[Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005266
German
Original Title:
Alemtuzumab, Cladribin, Dimethylfumarat, Fingolimod, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Ponesimod und Teriflunomid zur Behandlung Erwachsener mit hochaktiver schubförmig remittierender multipler Sklerose
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a20-60.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a20-60_multiple-sklerose_abschlussbericht_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Multiple Sclerosis, Relapsing-Remitting
- Alemtuzumab
- Cladribine
- Dimethyl Fumarate
- Fingolimod Hydrochloride
- Natalizumab
- Antibodies, Monoclonal, Humanized
- Sphingosine 1 Phosphate Receptor Modulators
- Anti-Inflammatory Agents, Non-Steroidal
- Immunosuppressive Agents
- Adult
Keywords
- Alemtuzumab
- Cladribine
- Dimethyl Fumarate
- Fingolimod Hydrochloride
- Natalizumab
- Ocrelizumab
- Ofatumumab
- Ozanimod
- Ponesimod
- Teriflunomide
- Multiple Sclerosis – Relapsing-Remitting
- Benefit Assessment
- Systematic Review
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.